Stoke Therapeutics (NASDAQ:STOK) is a biotechnology company focused on addressing the underlying causes of severe genetic diseases by upregulating protein expression with its proprietary RNA-based approach, TANGO (Targeted Augmentation of Nuclear Gene Output). The company aims to pioneer transformative therapies to improve the lives of individuals suffering from diseases caused by a single genetic mutation, such as Dravet syndrome, a severe form of epilepsy. Stoke Therapeutics is dedicated to advancing its lead candidate, STK-001, through clinical development for the treatment of Dravet syndrome, as well as expanding its pipeline to address other genetic conditions. The company's objectives include delivering breakthrough treatments to patients in need and establishing itself as a leader in genetic medicine by leveraging its TANGO technology to address currently untreatable conditions.